NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued on Tuesday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY stock opened at $0.61 on Tuesday. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08. The stock has a market cap of $3.55 million, a P/E ratio of -0.01 and a beta of 0.73. The company has a 50 day simple moving average of $0.65 and a two-hundred day simple moving average of $0.63.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.